284 related articles for article (PubMed ID: 29231062)
1. Promising immunotherapy for prostate cancer.
Henegan JC; Sonpavde G
Expert Opin Biol Ther; 2018 Feb; 18(2):109-120. PubMed ID: 29231062
[TBL] [Abstract][Full Text] [Related]
2. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in immunotherapy for the treatment of prostate cancer.
Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
[TBL] [Abstract][Full Text] [Related]
4. Development of novel immune interventions for prostate cancer.
Agarwal N; Padmanabh S; Vogelzang NJ
Clin Genitourin Cancer; 2012 Jun; 10(2):84-92. PubMed ID: 22409862
[TBL] [Abstract][Full Text] [Related]
5. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
6. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
Dong B; Minze LJ; Xue W; Chen W
Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
[TBL] [Abstract][Full Text] [Related]
7. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Cheng ML; Fong L
Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
[TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
[TBL] [Abstract][Full Text] [Related]
9. Advances in prostate cancer immunotherapies.
Basler M; Groettrup M
Drugs Aging; 2007; 24(3):197-221. PubMed ID: 17362049
[TBL] [Abstract][Full Text] [Related]
10. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in prostate cancer.
Sobol I; Thompson RH; Dong H; Krco C; Kwon ED
Curr Urol Rep; 2015 Jun; 16(6):34. PubMed ID: 25894495
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
Alberti C
G Chir; 2017; 37(5):225-235. PubMed ID: 28098061
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
14. Novel immunotherapy combinations for genitourinary cancers.
Al Harthy M; Redman J; Madan RA
Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
[TBL] [Abstract][Full Text] [Related]
16. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
Madan RA; Gulley JL; Kantoff PW
Cancer J; 2013; 19(1):50-8. PubMed ID: 23337757
[TBL] [Abstract][Full Text] [Related]
17. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
18. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
19. Integration of immunotherapy into the management of advanced prostate cancer.
Kantoff P; Higano CS
Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162
[TBL] [Abstract][Full Text] [Related]
20. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
Dawson NA; Roesch EE
Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]